| Name | Title | Contact Details |
|---|
TacMed Solutions™ was formed to develop quality, effective supplies and equipment for combat and tactical medicine. We knew what worked for us in that environment and wanted to share it with as many people as possible. Our products reflect our experience, situations we have faced and friends we have lost. Our goal is to prevent others from experiencing those losses by offering equipment that allows them to operate more efficiently and effectively. Minimizing preventable death in a combat or tactical environment is a realistic and attainable goal and we are proud to offer products that will help you reach it. All of our employees are former tactical medical professionals or have a close relationship with them. We maintain close ties with some of the most elite and experienced medics in the world and every one of our products must pass their evaluation before we put our name on it. We understand the principles of human performance as it relates to combat stress and design our products to complement that performance not complicate it. This approach to product development and evaluation leads to products that truly work in combat. We don`t design products to pass a structured laboratory test in a controlled environment or barely meet a requirement as a substitute. They are designed to function when there is no structure, when you have minimal supplies and very little time. When there is no one else there to help, and you probably have more than one casualty. You are trying to save lives while someone is trying to take yours. That is the environment of the tactical health care provider and that is where our products excel.
Magnolia Medical Technologies develops innovative medical products that achieve predictable, high-quality outcomes.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Reliance Medical is a Mason, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nashville Medical Group is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.